Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioral effects of fluoxetine and phenelzine

European Journal of Pharmacology

Volumn 459, Issue 2-3, 2003, Pages 221-230

  Holmes, Andrew ^a,b   Rodgers, R John ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

(Mouse); Antidepressant; Anxiety; Benzodiazepine; Elevated plus maze; Test experience

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BENZODIAZEPINE RECEPTOR; FLUMAZENIL; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EXPOSURE; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0037449467     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02874-1     Document Type: Article

References (73)

1. Artigas F. Limitations to enhancing the speed of onset of antidepressants - are rapid action antidepressants possible? Hum. Psychopharmacol. Clin. Exp. 16:2001;29-36.
2. 1A antagonists. Trends Neurosci. 19:1996;378-383.
3. Artigas F., Celada P., Laruelle M., Adell A. How does pindolol improve antidepressant action? Trends Pharmacol. Sci. 22:2001;224-228.
4. Ballenger J.C. Current treatments of the anxiety disorders in adults. Biol. Psychiatry. 46:1999;1579-1594.
5. Beaufour C.C., Ballon N., Le Bihan C., Hamon M., Thiebot M.H. Effects of chronic antidepressants in an operant conflict procedure of anxiety in the rat. Pharmacol. Biochem. Behav. 62:1999;591-599.
6. Belzung C., Le Guisquet A.M., Barreau S., Calatayud F. An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice. Behav. Pharmacol. 12:2001;151-162.
7. Blakely R.D., Berson H.E., Fremeau R.T. Jr., Caron M.G., Peek M.M., Prince H.K., Bradley C.C. Cloning and expression of a functional serotonin transporter from rat brain. Nature. 354:1991;66-70.
8. Blanchard R.J., Blanchard D.C. Crouching as an index of fear. J. Comp. Physiol. Psychol. 67:1969;370-375.
9. Blanchard R.J., Yudko E.B., Rodgers R.J., Blanchard D.C. Defense system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety. Behav. Brain Res. 58:1993;155-165.
10. Blier P., de Montigny C. Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors. Neuroscience. 16:1985;949-955.
11. Blier P., Pineyro G., el Mansari M., Bergeron R., de Montigny C. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann. N. Y. Acad. Sci. 861:1998;204-216.
12. Bourin M., Redrobe J.P., Hascoet M., Baker G.B., Colombel M.C. A schematic representation of the psychopharmacological profile of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry. 20:1996;1389-1402.
13. Canto de Souza A., Nunes de Souza R.L., Rodgers R.J. Anxiolytic-like effect of WAY-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience. Brain Res. 928:2002;50-59.
14. Cole B.J., Hillmann M., Seidelmann D., Klewer M., Jones G.H. Effects of benzodiazepine receptor partial inverse agonists in the elevated plus maze test of anxiety in the rat. Psychopharmacology. 121:1995;118-126.
15. Crawley J.N., Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm. Behav. 31:1997;197-211.
16. Dalvi A., Rodgers R.J. Behavioral effects of diazepam in the murine plus-maze: flumazenil antagonism of enhanced head dipping but not the disinhibition of open-arm avoidance. Pharmacol. Biochem. Behav. 62:1999;727-734.
17. Dawson G.R., Crawford S.P., Collinson N., Iversen S.D., Tricklebank M.D. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology. 118:1995;316-323.
18. Dyck L.E., Juorio A.V., Durden D.A., Boulton A.A. Effect of chronic deuterated and non-deuterated phenelzine on rat brain monoamines and monoamine oxidase. Naunyn-Schmiedeberg's Arch. Pharmacol. 337:1988;279-283.
19. Fernandes C., File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol. Biochem. Behav. 54:1996;31-40.
20. File S.E. One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze. Psychopharmacology. 100:1990;281-282.
21. File S.E. The interplay of learning and anxiety in the elevated plus-maze. Behav. Brain Res. 58:1993;199-202.
22. File S.E. Factors controlling measures of anxiety and responses to novelty in the mouse. Behav. Brain Res. 125:2001;151-157.
23. 1A-receptor ligands in dorsal raphe and ventral hippocampus. Pharmacol. Biochem. Behav. 54:1996;123-128.
24. File S.E., Zangrossi H. 'One-trial tolerance' to the anxiolytic actions of the benzodiazepines in the elevated plus-maze, or the development of a phobic state? Psychopharmacology. 110:1993;240-244.
25. File S.E., Mabbutt P.S., Hitchcott P.K. Characterisation of the phenomenon of one-trial tolerance to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology. 102:1990;98-101.
26. File S.E., Zangrossi H. Jr., Sanders F.L., Mabbutt P.S. Raised corticosterone in the rat after exposure to the elevated plus-maze. Psychopharmacology. 113:1994;543-546.
27. 1A receptor modulation of anxiety in two ethological animal tests. J. Neurosci. 16:1996;4810-4815.
28. File S.E., Gonzalez L.E., Gallant R. Role of the basolateral nucleus of the amygdala in the formation of a phobia. Neuropsychopharmacology. 19:1998;397-405.
29. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65:1995;319-395.
30. Griebel G., Rodgers R.J., Perrault G., Sanger D.J. Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze. Pharmacol. Biochem. Behav. 57:1997;817-827.
31. Griebel G., Curet O., Perrault G., Sanger D.J. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. Neuropharmacology. 37:1998;927-935.
32. Handley S.L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn-Schmiedeberg's Arch. Pharmacol. 327:1984;1-5.
33. Hascoet M., Bourin M., Couetoux du Tertre A.C. Influence of prior experience on mice behavior using the four-plate test. Pharmacol. Biochem. Behav. 58:1997;1131-1138.
34. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54:1996;21-30.
35. Holmes A. Transgenic and gene knockout approaches to the study of anxiety-like behavior in mice. Neurosci. Biobehav. Rev. 25:2001;261-273.
36. Holmes A., Rodgers R.J. Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for a qualitative shift in emotional state? Pharmacol. Biochem. Behav. 60:1998;473-488.
37. Holmes A., Rodgers R.J. Influence of spatial and temporal manipulations on the anxiolytic efficacy of chlordiazepoxide in mice previously exposed to the elevated plus-maze. Neurosci. Biobehav. Rev. 23:1999;971-980.
38. Holmes A., Rodgers R.J. Prior test experience abolishes the anxiolytic efficacy of chlordiazepoxide in the mouse light/dark exploration test. Behav. Brain Res. 122:2001;159-167.
39. Holmes A., Diffley E.P., Walton T.J., Brain P.F., Rodgers R.J. Lack of habituation of corticosterone response in mice repeatedly exposed to the plus-maze. J. Psychopharmacol. 12S:1998;A32.
40. Holmes A., Parmigiani S., Ferrari P.F., Palanza P., Rodgers R.J. Behavioral profile of wild mice in the elevated plus-maze test for anxiety. Physiol. Behav. 71:2000;509-516.
41. Johnston A.L., File S.E. Profiles of the antipanic compounds, triazolobenzodiazepines and phenelzine, in two animal tests of anxiety. Psychiatry Res. 25:1998;81-90.
42. Kreiss D.S., Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J. Pharmacol. Exp. Ther. 274:1995;866-876.
43. Lai C.T., Tanay V.A., Charrois G.J., Baker G.B., Bateson A.N. Effects of phenelzine and imipramine on the steady-state levels of mRNAs that encode glutamic acid decarboxylase (GAD67 and GAD65), the GABA transporter GAT-1 and GABA transaminase in rat cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1998;32-38.
44. Liebowitz M.R., Hollander E., Schneier F., Campeas R., Welkowitz L., Hatterer J., Fallon B. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr. Scand. 360:1990;29-34.
45. Lister R.G. The use of the plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
46. Londborg P.D., Smith W.T., Glaudin V., Painter J.R. Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. J. Affect. Disord. 61:2000;73-79.
47. Maki Y., Inoue T., Izumi T., Muraki I., Ito K., Kitaichi Y., Li X., Koyama T. Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Eur. J. Pharmacol. 406:2000;411-418.
48. Matsubara M., Suzuki S., Miura K., Terashima M., Sugita S., Kimura H., Hatsuda S., Mori T., Murakami H., Hayashi T., Ohta T., Ohara M. Electrophysiologic analysis of antidepressant drug effects on the GABA(A) receptor complex based upon antagonist-induced encephalographic power spectrum changes. Neuropsychobiology. 42:2000;149-157.
49. McGregor I.S., Dielenberg R.A. Differential anxiolytic efficacy of a benzodiazepine on first versus second exposure to a predatory odor in rats. Psychopharmacology. 147:1999;174-181.
50. Mcllwain K.L., Merriweather M.Y., Yuva-Paylor L.A., Paylor R. The use of behavioral test batteries: effects of training history. Physiol. Behav. 73:2001;705-717.
51. Nunes de Souza R.L., Canto de Souza A., Rodgers R.J. Effects of intra-hippocampal infusion of WAY-100635 on plus-maze behavior in mice: influence of site of injection and prior test experience. Brain Res. 927:2002;87-96.
52. Nutt D.J., Malizia A.L. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br. J. Psychiatry. 179:2001;390-396.
53. Nutt D.J., Smith C.F., Bennett R., Jackson H.C. Investigations on the "set-point" theory of benzodiazepine receptor function. Adv. Biochem. Psychopharmacol. 47:1992;419-429.
54. Parent M.B., Master S., Kashlub S., Baker G.B. Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum. Biochem. Pharmacol. 63:2002;57-64.
55. Paslawski T., Treit D., Baker G.B., George M., Coutts R.T. The antidepressant drug phenelzine produces antianxiety effects in the plus-maze and increases in rat brain GABA. Psychopharmacology. 127:1996;19-24.
56. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
57. Rickels K., Smith W.T., Glaudin V., Amsterdam J.B., Weise C., Settle G.P. Comparison of two dosage regimens of fluoxetine in major depression. J. Clin. Psychiatry. 46:1985;38-41.
58. Rodgers R.J. Animal models of 'anxiety': where next? Behav. Pharmacol. 8:1997;477-496.
59. Rodgers R.J., Cole J.C. The elevated plus-maze: pharmacology, methodology and ethology. Cooper S.J., Hendrie C.A. Ethology and Psychopharmacology. 1994;9-44 Wiley, Chichester.
60. Rodgers R.J., Shepherd J.K. Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and the light/dark tests of anxiety in mice. Psychopharmacology. 113:1993;237-242.
61. Rodgers R.J., Lee C., Shepherd J.K. Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology. 106:1992;102-110.
62. Rodgers R.J., Cole J.C., Aboualfa K., Stephenson L.H. Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol. Biochem. Behav. 52:1995;805-813.
63. Rodgers R.J., Johnson N.J., Cole J.C., Dewar C.V., Kidd G.R., Kimpson P.H. Plus-maze retest profile in mice: importance of initial stages of trail 1 and response to post-trail cholinergic receptor blockade. Pharmacol. Biochem. Behav. 54:1996;41-50.
64. Rodgers R.J., Johnson N.J.T., Carr J., Hodgson T.P. Resistance of experientially induced changes in murine plus-maze behaviour to altered retest conditions. Behav. Brain Res. 86:1997;1-77.
65. Rodgers R.J., Haller J., Holmes A., Halasz J., Walton T., Brain P.F. Corticosterone response to the plus-maze: high correlation with risk assessment in rats and mice. Physiol. Behav. 68:1999;47-53.
66. Rogers D.C., Fisher E.M., Brown S.D., Peters J., Hunter A.J., Martin J.E. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm. Genome. 8:1997;711-713.
67. Rupniak N.M., Carlson E.C., Harrison T., Oates B., Seward E., Owen S., de Felipe C., Hunt S., Wheeldon A. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology. 39:2000;1413-1421.
68. 1A autoreceptor. J. Neurosci. Methods. 34:1990;83-90.
69. Stein D.J., Berk M. Selective serotonin reuptake inhibitors in the anxiety disorders. Int. Clin. Psychopharmacol. 15:2000;S1-S63.
70. Stokes P.E., Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin. Ther. 19:1997;1135-1250.
71. Tanay V.M., Greenshaw A.J., Baker G.B., Bateson A.N. Common effects of chronically administered antipanic drugs on brainstem GABA(A) receptor subunit gene expression. Mol. Psychiatry. 6:2001;404-412.
72. Tunnicliff G., Schindler N.L., Crites G.J., Goldenberg R., Yochum A., Malatynska E. The GABA(A) receptor complex as a target for fluoxetine action. Neurochem. Res. 24:1999;1271-1276.
73. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. U. S. A. 95:1998;3239-3244.